Obstructive airways inflammatory diseases sometimes show overlapping symptoms that hinder their early and correct diagnosis. Current clinical tests are tedious and are of inadequate specificity in special population such as the elderly and children. Therefore, we are developing tandem mass spectrometric (MS/MS) methods for targeted analysis of urine biomarkers. Recently, protonnuclear magnetic resonance ( 1 H-NMR) analysis proposed 50 urinary metabolites as potential diagnostic biomarkers among asthma and chronic obstructive pulmonary disease (COPD) patients. Metabolites are divided into 3 groups based on chemical nature. For group 1 (amines and phenols, 19 urinary metabolites), we developed and validated a high performance liquid chromatographic (HPLC)-MS/MS method using differential isotope labeling with dansyl chloride. Method development included the optimization of the derivatization reaction, the MS/MS conditions, and the chromatographic separation. Linearity varied from 2 to 4800 ng/mL and the use of 13 C2-labeled derivatives allowed for the correction of matrix effects as well as the unambiguous confirmation of the identity of each metabolite in the presence of interfering isomers in urine. Despite the challenges associated with method validation, the method was fully validated as per the food and drug administration (FDA) and the European medicines agency (EMA) recommendations. Validation criteria included linearity, precision, accuracy, dilution integrity, selectivity, carryover, and stability. Challenges in selectivity experiments included the isotopic contributions of the analyte towards its internal standard (IS), that was addressed via the optimization of the IS concentration. In addition, incurred sample analysis was performed to ensure that results from patient samples are accurate and reliable. The method was robust and reproducible and is currently being applied in a cohort of asthma and COPD patient urine samples for biomarker discovery purposes.
Introduction
Asthma and chronic obstructive pulmonary disease (COPD) are a major cause of morbidity and they impose a huge economic burden with more than 600 million patients are currently diagnosed with these illnesses [1] . Despite the distinct differences in the pathophysiology of asthma and COPD, their diagnosis using currently available diagnostic tools is difficult in a typical primary care setting [2] [3] [4] [5] [6] . It is common for some patients to experience an overlap in the clinical presentations of asthma and COPD or even have both as co-existing conditions [2, 7, 8] . This is particularly valid with asthmatic smokers, elderly with normally declined lung functions, and those with more severe asthma [2] [3] [4] . Correct diagnosis is crucial as each disease has different therapeutic strategies [4] . Accordingly, with the inaccessibility of accurate diagnostic tools in typical primary care settings, the diagnosis of asthma and COPD is too often based on history as described by the patient. Therefore, recent work has focused on novel approaches to diagnosis.
Metabolomics is the study of the end products of cellular metabolism in healthy and diseased states [9] [10] [11] [12] . Applied metabolomics in medicine aims to link different biochemical pathways with disease diagnosis, severity, and therapeutic response [11, 12] . It has demonstrated promising outcomes in biomarker discovery and in personalized medicine [11, 13, 14] . Among the various biological fluids, urine is ideal for metabolomic analysis. Its collection is non-invasive and it has richer metabolite content in comparison to blood, saliva, exhaled breath condensate or bronchoalveolar lavage [9, 10] . Beyond lung disease, urine metabolomics has been mostly studied for improving the detection of various types of cancer [15, 16] , including that in the renal system [17, 18] . Investigation of the urine metabolome has also included, but not limited to, the diagnosis of jaundice syndrome [19] and chronic heavy metal toxicity [20] , the understanding of pathophysiology of depression [21] and the prediction of acute renal injury following cardiopulmonary bypass surgery in children [22] .
Previous metabolomic studies on asthma or COPD subjects have been conducted in different biological fluids mostly in untargeted/semi-targeted approach [9, 10] . For instance, a 1 H-NMR study of COPD blood samples showed lower levels of alanine, valine and isoleucine in comparison to healthy individuals [23] . Using the same platform, exhaled breath condensate (EBC) of COPD patients revealed significantly lower levels of valine and lysine, while the levels of serine and tyrosine were significantly higher in comparison to controls [24] . An increase in arginine levels and a decrease in glutamine, valine and isoleucine levels were also observed in the serum of COPD patients [25, 26] . On the other hand, the serum of asthmatic patients, using 1 H-NMR, showed low levels of arginine along with valine and alanine, whereas; high histidine and glutamine levels were observed [27] . It can be concluded from these studies, that amino acids metabolism is an important pathway in the pathogenesis of asthma and COPD.
Pertaining to urine, comparisons of the metabolomic profiles of healthy participants with either asthmatic [28, 29] or COPD subjects [30, 31] have been reported. Despite providing useful metabolomic information, these 'disease/no disease' studies are less interesting in clinical practice.
People know when they have chronic trouble breathing. The more important question is knowing the cause or type of chronic lung disease and the type of treatment it requires. Accordingly, metabolomics investigating the disease severity in asthma or COPD shows more promise for translational and personalized medicine in primary care settings [32] [33] [34] . However, previous
reports either involved few specific classes of metabolites (e.g. volatile metabolites) [32, 33] or resulted in the identity confirmation of very few metabolites [34] .
To move to this important next stage, accurate targeted analysis is needed to clinically validate potentially therapeutic biomarkers. Contrary to the progress achieved in untargeted metabolomics, targeted quantification of endogenous metabolites is still at its infancy. Challenges in absolute quantification include the wide variations in metabolite concentration with diverse physicochemical properties [12] . In addition, neither endogenous metabolite-free matrices nor appropriate regulatory guidelines for the validation of bioanalytical methods for endogenous metabolites are available [35] [36] [37] .
To the best of our knowledge, only 1 semi-targeted 1 H-NMR study investigated the differences in the urine metabolome between asthma and COPD patients [38] . Based on this investigation, a group of urine metabolites were suggested as potential diagnostic biomarkers differentiating asthma and COPD. Before these 1 H-NMR based metabolites can be used in a clinical lab, they require further validation. The suggested biomarkers were sub-divided into 3 groups based on their functional groups. Group 1 contains 19 metabolites that bear a primary amine, secondary amine or a phenolic group (Table 1) . Group 2 contains 17 organic acids metabolites, whose identities and their validated quantification method will be described in a separate publication. Finally, group 3 contains 11 miscellaneous metabolites; including: quaternary ammonium compounds, sugars and nucleic acids as well as amino and organic acids that were not compatible with the developed methods for groups 1 and 2. Herein, we developed a fully validated LC-MS/MS method for the absolute quantification of a subset of 19 potential biomarker metabolites for the diagnosis of asthma and COPD. We adopted the deferential isotope labeling (DIL) approach [39] for the development of the quantification method. Amine and/or phenol functional groups contained within our metabolites can be derivatized with 12 C2/ 13 C2-Dansyl chloride (DNS-Cl) as described by Guo et al. [39] . DIL has been mostly used for relative quantification purposes of the metabolome [39] [40] [41] [42] , however, despite the usefulness of published semi-quantitative studies using DIL-DNS-Cl, we are required by regulatory bodies a full validation of the analytical method since clinical data will be obtained. The presented work discusses the usefulness of DIL strategy for absolute biomarker quantification and approaches to address the challenges typically faced in endogenous quantitative metabolomics. 
Experimental

Materials and chemicals
All chemicals were purchased from Sigma Aldrich (Oakville, ON, CA) unless otherwise stated. 3-bromo tyrosine (98%) was purchased from abcam (Cambridge, UK) and sarcosine (99.4%) was purchased from Santa Cruz biotechnology (Santa Cruz, CA, USA). Optima® LC-MS grade acetonitrile (ACN) and water was purchased from Fischer Scientific (ON, CA). The concentration of creatinine within subject samples was determined using Jaffe's colorimetric reaction using QuantiChrom™ creatinine assay kit (QC, CA) [43, 44] . C2-labeled reagent was not available commercially. Accordingly, it was synthesized in house along with the non-isotopic form in a 2-step reaction procedure [39, 45, 46] . Synthesis protocol was modified from published methodologies in order to produce the highest yield of DNS-Cl (Supplemental materials (Appendix I, Figure 1) ). The combination of the 2 step reaction is novel to the published methodology reported for the production of 12 C2/ 13 C2-DNS-Cl in metabolomics [39] . The use of the commercially available 12 C2-DNS-Cl was avoided because of its inadequate purity demonstrated by the precipitation of a white residual powder in ACN at the working concentration of the reagent. On the other hand, the 2 synthesized forms of DNS-Cl ( 12 C2 -and 13 C2-) were readily soluble in ACN without any insoluble matter, and were consequently used throughout the work.
Synthesis of
Patients characteristics
Patients were enrolled after obtaining written informed consent, as approved by the University of Saskatchewan's biomedical research ethics board. Patients, seen at the Royal university hospital, Saskatoon, SK, were selected within an age group of 40-69 years old and were clinically assessed by a physician. Samples analyzed were age and gender matched as much as possible. No diet or time of collection restrictions were followed as the aim of the experiment was to identify metabolites that were sufficiently altered between asthma and COPD patient groups at a level that surpasses such variation. Urine samples collected from 42 patients were analyzed in this work. 
Preparation of standard solutions
A standard stock solution for each standard reference analyte was separately prepared at 3 mg/mL in 50% ACN. For solubility/sensitivity aspects, the following exceptions were made; sarcosine and asparagine were prepared at 1.5 mg/mL in 50% ACN, tyrosine at 3 mg/mL in 0.1 M HCl and 3-bromotyrosine and 3-chlorotyrosine at 3 mg/mL in water.
A.
12
C2-derivatized analytes stock solution preparation
Aliquots from the aforementioned analyte standard stock solutions were combined to prepare a standard working stock solution mixture of the 19 underivatized analytes at concentrations varying from 12.5 to 160 µg/mL. The basic derivatization reaction was adopted from Dr. Liang Li's group, University of Alberta, Canada [39, 47] . However, changes to the experimental conditions were needed to optimize the reaction. 
Instrumentation
LC-MS/MS analysis was performed on a 1200 Agilent HPLC system (Mississauga, ON, Canada)
interfaced to an AB Sciex 4000 API QTRAP instrument (AB Sciex, Concord, ON, Canada). The optimized instrumentation settings for chromatographic separation, derivatized analytes identification and quantification are compiled in Supplemental Tables (Table 1 ).
Method Validation
A.
Matrix effects and suitability of the blank surrogate urine
We introduced the blank surrogate urine matrix approach to simulate derivatized urine and to be used in standards and QC samples preparation as well as in the dilution of highly concentrated patient samples. Matrix effects encountered from the blank surrogate urine matrix were evaluated according to equations 1, 2 as recommended by the European medicines agency (EMA) [36] using high QC (HQC; 83% of upper limit of quantification (ULOQ)) and low QC (LQC; 2.6 × the lower limit of quantification, LLOQ) samples. Six replicates at low and high QC levels were prepared as described under 12 C2-derivatized analytes stock solution preparation and spiked into 6 different surrogate urine matrices prepared from 6 different sources of control urine according to the procedure in 2.5.A. The absolute peak areas of the derivatized analytes were compared to those of analogues QC samples prepared in 50% ACN (i.e. neat solvent) [35, 36, 48] . The EMA also recommends the calculation of the CV% of IS normalized matrix factor (MF), where a CV% value of less than 15% indicates acceptable interferences from the matrix [36] .
Equation 1: Matrix factor (MF) = B/A Equation 2: IS normalized MF = MF analyte/MF IS
Where B is the absolute peak area of the analyte in surrogate urine matrix and A is the absolute peak area of the analyte in neat solvent (50% ACN).
In addition, the U.S. Food and Drug Administration (FDA) recommends the comparison of the slopes of the calibration curves as a mean to evaluate matrix effects in ligand binding assays. [35] This approach is adopted to test the suitability of the surrogate blank urine as a valid substitute matrix for real derivatized urine. The methodological approach is described in details in Appendix II, supplementary materials.
B. Selectivity
Six double blanks containing only solvents and acidic/basic reagents (i.e., no analytes or DNS-Cl)
were prepared and spiked into 6 blank surrogate matrices prepared from 6 different sources of 
C. Carry over effects
Carry over effects were investigated according to EMA guidelines [36] . The responses in blank solutions injected after highly concentrated samples were compared to that of the LLOQ. Carry over effects can be deemed insignificant if the interference observed in the subsequent blanks is less than 20% and 5% of LLOQ for the analyte and its corresponding IS, respectively [36] .
D. Linearity
For the construction of 8 points-calibration curves, volumes from the 12 C2-derivatized analytes stock solution were serially diluted with 50% ACN. Forty microliters of the appropriate dilution were mixed with 60 µL blank surrogate urine matrix containing 10 µL 13 C2-derivatized ISs solution. Regression equations of the peak area ratios vs. the corresponding concentrations were generated using the least square regression model with a weighing factor of 1/x 2 . For accepting the calibration curve for each analyte; the back calculated concentration of the calibration points had to fall within 15% of the nominal concentration with the exception of the LLOQ which can tolerate up to 20% difference. At least 75% (6 out of 8) of the calibration points must fulfil this criterion [35, 36, 49] . The lower limit of quantification was determined according to the signal-to-noise ratio. The analyte response at the lowest end of the calibration curve should be at least 5 times higher than the signal encountered at the blank [35, 36] .
E. Intra-and inter-day accuracy and precision
The intra-and inter-day accuracy and precision of the developed method were assessed, on 3 non consecutive days, using 4 QC levels covering the range of the calibration curves [35, 36, 49] . The HQC was set at 83% of the ULOQ. The middle QC (MQC) was set at 42% of the calibration range and the lower QC (LQC) was 2.6 times the concentration of the LLOQ. The LLOQ is the fourth level of the QC samples. QC samples were prepared from different stock solutions in 6 replicates, spiked into surrogate urine matrix and analyzed on 3 different days for the evaluation of inter-day accuracy and precision. The mean of the observed concentration must be within 15% of the nominal concentration for all levels with the exception of the LLOQ (within 20%). In addition, it must not deviate from the nominal concentration more than 15 % with the exception of the LLOQ in which a coefficient of variation (CV%) of 20% is still acceptable [35, 36, 49] .
F. Stability studies
Stability was assessed using freshly prepared QC samples at multiple levels including benchtop stability, autosampler stability, freeze thaw stability, and short-and long-term stability. Details of the stability experiments are shown in Appendix III, supplementary materials.
G. Dilution integrity
An aliquot from 12 C2-derivatized analytes stock solution was spiked into surrogate urine matrix to produce a simulated urine sample in which the concentrations of the analytes are 6.7 folds higher than the ULOQ. Aliquots from this solution were 5, 10 and 20 fold diluted with blank surrogate urine and 50 µL of each were mixed with 50 µL of 50% ACN containing 10 µL of 13 C2-derivatized
ISs. Patients' samples that were initially analyzed early in the method development phase and were found to contain analytes at concentrations above their ULOQ, especially for histidine, were used to evaluate the investigated dilution range. After derivatization, these patients' urine samples were diluted using blank surrogate urine matrix and reinjected into the system. This experiment was of particular importance in order to confirm the appropriateness of the tested dilution range before the application of the validated method on the study samples.
H. Incurred sample analysis
In addition to QC samples, the accuracy and precision of the developed method were also evaluated on patient urine samples. Four patient samples were selected so that they would contain very low, very high and middle creatinine values amongst the analyzed patient samples. Sample analysis was done over 2 consecutive days and a third day which was 2 weeks apart. The concentrations of the analytes obtained from their reanalysis should be within 20% of their mean for at least 67% of the repeats [36] . Since, guidelines adopt similar cut-off values for the acceptance of method accuracy and precision, a CV% value of up to 20% was also deemed appropriate for the evaluation of the precision of the analysis.
Analysis of patient urine samples
Asthma and COPD patient urine samples were processed as described under 2.5.B. along with calibration and validation standards. The analytical run was started by equilibrating the instrument with triple injections of a HQC sample [50] . This was done to ensure the acceptable performance of the system before the analysis of a sample batch [50] . The batch was also ended by triple injection of the high QC sample to ensure system suitability throughout the batch [50] . 
Results and Discussion
Rationale for adopting DIL strategy
DNS-Cl is a well-established derivatizing reagent that readily reacts with primary and secondary amines as well as phenols in alkaline medium [51] . It is, therefore, an ideal choice for the targeted 19 metabolites. Chemical derivatization enhances the chromatographic separation of such polar and low molecular weight metabolites on conventional reversed stationary phases (e.g. C18) [39] .
In addition, derivatization unifies, to some extent, the physicochemical properties of the produced derivatives bearing the same signature dansyl moiety [39] . Derivatization can also improves ESI ionization [39] [40] [41] and the introduced tag, such as DNS shift low molecular weight metabolites by 234 Daltons out of the low m/z region that typically exhibits high background noise, allowing for improved detectability [39] .
Most importantly, DIL can address one of the major hurdles in absolute metabolite quantification that is the availability of suitable internal standards (IS). Structural analogues cannot guarantee the accuracy and precision of quantification [39, 52] and the use of isotopically-labeled ISs is challenging due to their price or commercial availability [39, 53] . DIL technique uses 2 isotopologues of a derivatizing reagent to produce light and heavy (deuterated or 13 C-containing)-derivatized metabolites. DIL using DNS-Cl allowed for the generation of a stable isotope IS for each target metabolite of the 19 targeted molecules, as discussed below.
Method development
Optimization of the derivatization reaction and sample preparation
Since the metabolites of interest are endogenous in nature; it was essential to optimize the reaction conditions in patient urine samples and in the standard mixture (data not shown). Each A volume of 30 µL of 0.5 M carbonate/bicarbonate buffer (pH 9.4), was sufficient to create the basic medium necessary for a reproducible dansylation reaction in urine and standard solutions.
Higher volumes of the buffer were associated with an incompatible high salt content manifested as phase separation in the reaction mixtures. Although the basic method was based on published work [39, 47] , the optimization experiments favored a shorter reaction time with much less reagent content, and consequently, less contamination/ion suppression in the mass spectrometer.
Another vital element of the derivatization reaction is the composition of the organic/aqueous medium. A medium of 54% ACN was essential to prevent phase separation of the organic DNSCl solution in the reaction mixture following derivatization. Interestingly, a similar observation of solvent incompatibility was reported along with the formation of an unknown precipitate in the reaction medium that contained 33% ACN [42] . However, increasing the ACN content to 50% was sufficient to overcome both issues [42] . between each analyte and its corresponding IS. In addition, the double tagged metabolites were of higher hydrophobicity and were consequently well separated from other mono-tagged metabolites.
The enhanced ionization of the double tagged metabolites due to the higher organic solvent content needed for their elution allowed for higher sensitivity during quantification.
Optimization of the mass spectrometric detection and quantification
The MS/MS fragmentation pattern for each derivatized metabolite was generated and rationalized.
Product ions observed from the collision induced dissociation (CID)-MS/MS of the derivatives contained the dansyl moiety and that was in agreement with the reported fragmentation behavior of the reagent [47] .
The most abundant product ions for all metabolites are observed at m/z 157.09 and m/z 170.1, corresponding to the methyl amino naphthalene and dimethylamino naphthalene charged moieties, respectively ( Figure 1 ) [47] . In order to allow for adequate mass spectrometric separation at unit resolution between each analyte and its IS, it was favorable to maintain the isotopically labeled methyl groups within the selected MRM transitions to achieve a mass difference of 2 mass units.
For this reason, the product ion at m/z 170.1 was selected as the quantifier transition for all analytes.
The collision energy and declustering potential were optimized for each analyte for maximum generation of the quantifier product ion. Additionally, diagnostic product ions were identified, whenever possible, for each analyte to confirm its identity in patient urine samples (Supplemental Tables (Table 1) ). 
Optimization of the chromatographic separation
Adequate separation of all analytes was achieved over 33 minute run using the optimized binary gradient mobile phase system (Figure 2) . The presence of a perfectly co-eluting IS bearing 13 C2-carbons for each metabolite aided in its unambiguous identification in complex patient urine samples. For instance, urine samples contained multiple isomers of isoleucine that could also react with dansyl chloride. The secondary diagnostic product ion at m/z 350 was also present within the closest eluting peak to isoleucine which can be probably attributed to leucine (Supplemental materials, Appendix IV, Figure 2) ). However, the combination of retention time matching with standard isoleucine peak in addition to pairing with 13 C2-derivatized IS added absolute confidence in its quantification. LC base-line resolved unidentified isomeric dansylated metabolites peaks were also noticed for alanine and arginine. 
Method validation
The guidelines for bioanalytical method validation issued by the FDA [35, 49] and EMA [36] were followed. Despite being inclusive platforms for pharmaceutical/biomedical analyses, these guidelines were not always sufficient to address the challenges associated with endogenous metabolite quantification. In the following discussions; validation criteria of these guidelines are discussed along with atypical analytical/statistical approaches that were adopted to meet the unforeseen challenges identified during method development and validation.
Evaluation of blank surrogate urine matrix suitability
The FDA recommends the use of the same sample matrix for the construction of calibration curves and QC samples [35, 49] . However, this is not feasible when conducting a metabolomic study, where the metabolites of interest are endogenously present in the blank matrix. With the absence of guidelines on the acceptable matrix for standard preparations in metabolomics, various strategies have been employed including the use of solvents of reconstitution, simulated and stripped matrices, biological fluids with low endogenous concentration of metabolites, standard addition method or deuterated surrogate analytes [37, [55] [56] [57] .
On the other hand, underivatized urine was recently used as a surrogate matrix to which derivatized analytes were added [58] . The latter approach seemed, in principle, as the best strategy to adopt in this work. However, the derivatization procedure involved the addition of Na2CO3/NaHCO3 buffer, NaOH and FA that could change the nature of the urine (i.e. the matrix). Therefore, we introduced the surrogate blank urine matrix approach. Modified student t-test was used for the comparison between surrogate and derivatized matrices [58, 59] . t-test values were always lower than t-critical values at p= 0.05 suggesting the insignificant difference between both matrices. Therefore, the use of the surrogate urine matrix provided the most accurate concentration within the real derivatized patient samples (Supplemental Tables (Table 2) ).
Evaluation of matrix effects
The FDA states that the identification and elimination of matrix effects should be investigated during the development phase of an LC-MS/MS method, however, it does not provide any guidelines on the evaluation of such effects [35] . On the other hand, specific guidelines on the evaluation of matrix effects have been compiled by the EMA [36] . We found that the matrix factor was 96-130%, where, the majority of analytes suffered from low ion enhancement effect (Supplemental Tables (Table 3) ). This effect, not commonly seen in MS, was further confirmed through the comparison of the slopes of calibration curves generated in surrogate blank urine and neat solvent (50% ACN) (Supplemental materials, Appendix V (Figure 3) ). The vast variation in the obtained slopes further confirmed the unsuitability of the solvent as a substitute to the surrogate blank urine or derivatized urine samples (Supplemental materials, Appendix V, (Figure 3) ).
The CV% of IS normalized MF was lower than 15% in the developed method. In fact, the average values of the IS normalized MF were almost close to unity for all metabolites which indicates a very close similarity in the MS response between the analyte and it's IS, typically satisfied with the use of isotope coded IS (Supplemental Tables (Table 3 )) [57] . As such, the elution of a pair of chemically and physically similar compounds provides the best correction of matrix effects encountered from the urine.
Selectivity
Selectivity is described as the ability of the analytical method to unequivocally identify and quantify the analyte of interest in the presence of other components within a biological matrix [35, 36] . The FDA recommends the use of 6 different sources of the blank biological matrix to confirm the selectivity at the LLOQ. However, the acceptance values for a selective method were not suggested [35] . On the other hand, the EMA guidelines specify that within the double blanks, interferences should be less than 20% and 5% of LLOQ of the analyte and its corresponding IS, respectively [36] .
As seen in Table 2 , interferences encountered at the analyte and the IS channels for the 19 metabolites were found to be less than 14 and 2%, respectively. If only these guidelines were to be followed, such results would be sufficient to confirm the selectivity of the developed method for the 19 metabolites [35, 36] . However, due to the use of 13 C2-labeled internal standards that differ from their 12 C2-counterparts by merely 2 mass units, other challenges were associated with the IS purity and its natural isotopic contribution. This necessitated extra analytical assessments which were not specifically mentioned in the currently available bioanalytical method validation protocols. Such challenge is expected as clinical metabolomics is relatively a new area of investigation with little reports available on validated methods for absolute quantification.
The first interference, IS purity, is expected to arise from any 12 C2-DNS-Cl impurity in the C2-impurities were then evaluated at the analytes channel. As shown in Table 2 , these interferences were below 20% for all analytes; in fact all of them were below 12% with the vast majority below 7% (Table 2 ). This assessment confirms the adequate purity of the 13 C2-reagent and accordingly, the adequate purity of the IS-produced derivatives. For singly tagged compounds, the isotopic interference is more significant at the higher end of the calibration curve. At high concentrations of the analyte, its [M+H+2] + isotopic peak concomitantly increases resulting in a false increase in the IS peak area also being integrated at the [M+H+2] + channel. Consequently, a possible false negative estimation of the analyte response, expressed as a ratio relative to the IS, is possible leading to a non-linear relationship (Supplemental materials, Appendix VI (Figure 4) ). The isotopic contribution can be corrected either through subtraction or applying algorithm programs for deisotoping or via narrowing the linear range to avoid the significant contribution of the analyte at higher concentration [60] [61] [62] . Neither of these approaches were suitbale solution during the development/validation phase of this method, taking into account that a wide linear range was needed to cover the vast variation in concentrations among different metabolites. In addition, each metabolite can also considerably vary in concentration among urine samples depending on the hydration state of a patient. And for the sake of the method's simplicity, an extra correction step that would need an in-house computer program was sought to be avoided.
Alternately, another approach was adopted in which the concentration of the IS is increased so that the effect of the isotopic contribution from its analyte become negligible [60] . Logically, the maximum possible isotopic contribution would be encountered at the ULOQ. For this reason, triplicates of the ULOQ were prepared without the inclusion of the IS and were analyzed. The mean response due to the contribution of the analyte's isotopic peak was calculated at the IS's channel. ISs spiked at concentrations equivalent to 66% of the ULOQ resulted in isotopic interferences less than 3% in the IS's peak area which did not compromise the validity of method's linearly, accuracy and precision (Table 1 , Supplemental materials, Appendix VI, (Figure 4) ). 
C2-DNS-Cl
Carry over effects
No specific recommendations are available in the FDA guidelines for the evaluation of carry over effects, therefore, the EMA guidelines were used [35, 36] . Briefly, blank urine samples were analyzed following the injection of the ULOQ of the calibration curve as well as selected patient samples with high analyte concentrations. The responses obtained at the analyte channel in these blank solutions did not exceed 20% of that of the LLOQ indicating a negligible carry over (Supplemental Tables (Table 3) ). However, during the processing of a preliminary batch of 12 patients' samples, 2 metabolites in 2 samples showed carry over effects in their subsequent blank injections. No relationship was identified between the observed carry over effects and the contained analyte concentration; in fact, the analytes were within their linear ranges. This observation can be probably explained by the late elution of residues that had been retained on the column from previously highly concentrated solutions injected over time [57] .
To further avoid the rare possibility of carryover, we routinely injected blank samples after the ULOQ or HQC. Patient samples were also arranged ascendingly as per their creatinine values. The frequency of blank injection was increased towards the analysis of patient samples with high creatinine values. The autosampler needle was also washed using 5% isopropanol between the injected samples.
Lower limit of quantification and linearity
The LLOQ was determined based on the regulatory guidelines, in which, at the LLOQ, each analyte peak area mean (n=6) is at least 5 times higher than that observed at the double blank [35, 36] . For validating method linearity, a set of 8 calibration standards was used to construct a 200 fold linear curve for each derivatized analyte over the concentration ranges compiled in Supplemental Tables (Table 4 ). At least 75% of the calibration standards; 6 points including the LLOQ and ULOQ, showed acceptable deviations from their nominal values (±20% for LLOQ, ±15% for the other points). As seen in Supplemental Tables (Table 4) , satisfactory linear relationships were achieved (r 2 ≥0.990).
Linearity was first constructed using the simple least square regression model. In order to assess the homoscedasticity of the regression analysis; an F-test for the variances of LLOQ and HQC samples was conducted [63] . For all analytes, Fexperimental was larger than Fcritical indicating the necessity of a weighing factor to correct for the influence of the standard deviation of the large concentrations on the lower ones (Supplemental Tables (Table 5) ). Factors of 1/x and 1/x 2 were tested and CV% for each calculated regression concentration was computed against the nominal value. For all analytes, a factor of 1/x 2 resulted in the least sum of absolute CV% values across the whole calibration range, and consequently, 1/x 2 was used for curves weighing (Supplemental Tables (Table 5) ) [63] .
Intra-and inter day accuracy and precision
As seen from the data gathered in Supplemental Tables (Tables 6 and 7) , acceptable intra-and inter-day accuracies were demonstrated through the % recovery (%R) values that were between 85% and 115% at all levels, as per the FDA and EMA guidelines [35, 36] . Intra and inter-day precision was also acceptable with a CV% less than 17% for the LLOQ and less than 15% for all other levels.
Stability
Stability studies were mainly conducted to ensure that the concentrations of the derivatized metabolites are not varied under conditions that are likely to be encountered during sample processing and analysis. On a routine basis, 3 hours was the average sample processing time for a set of 15 patient samples along with the needed standards and QC solutions. For this reason, HQC and LQC samples (5 replicates) were processed as described and they were set aside for an additional 4 h period at room temperature. QC samples analyzed against freshly prepared calibration standards were stable for 4 h, where their % R values were between 95% and 112%
and their CV% values were less than 10% (Supplemental Tables (Table 8) ).
In addition to sample processing times, the relatively lengthy chromatographic run time necessitated the evaluation of the autosampler stability. QC samples were found stable for 48 h at 4 ºC (Supplemental Tables (Table 8 )), thus allowing for overnight collection of data from patient samples.
Freeze-thaw stability was also evaluated by exposing the prepared QC samples for 3 cycles of freezing to -80 ºC and thawing to room temperature. Freezing time in each cycle was not less 12
h. Again, derivatized QC samples were found stable (Supplemental Tables (Table 8) ). Although our standard operating procedure recommends the analysis of freshly prepared patient samples, the freeze-thaw stability of the processed samples showed that refreezing is possible during unforeseen instrument down times.
Short and long term storage stability for 2 weeks and 3 months, respectively, was also appraised.
From the data gathered (Supplemental Tables (Table 8 )), derivatized samples remained stable after a 2 week storage period. However, the samples were not stable when stored for a longer period of time as the accuracies ranged from 75% to 89.9%. This finding was not of a concern as the derivatized samples are unlikely to be reanalyzed after a 3 month storage period. Alternatively, a freshly thawed urine sample can be analyzed if needed. Additionally, data gathered in
Supplemental Tables (Table 8 ) for evaluating 3-month stock stability showed acceptable accuracy and precision of the analyzed QC samples.
Finally, the stability of underivatized urine (i.e. the metabolome stability) while being stored at -80 ºC, was assessed. An aliquot of a selected patient sample was thawed, processed and analyzed against a freshly prepared calibration curve once monthly over a 4 months period. The precision of the analysis for the majority of the quantified metabolites was acceptable as demonstrated by the CV% values that were less than 15%. The only metabolite outliers were arginine (15.97%) and sarcosine (51.3%) (Supplemental Tables (Table 8) ). The unacceptable CV% for sarcosine can be attributed to its instability on the 3 rd and 4 th months of analyses. There is a common consensus that lower temperatures of storage can preserve the metabolomic profile of biological samples.
Unfortunately, a comprehensive study that compares accurate metabolomes quantities is lacking, A recent review by Khamis el al [64] provided more information on the published literature regarding urine metabolome stability under different temperatures.
Dilution integrity Dilution integrity was tested by mixing 12 C2-derivatized analytes stock solution with blank surrogate urine matrix at ratio of 4:1. The obtained data demonstrates the acceptable accuracy and precision where the %R values were within ±15% and were not deviating by more than 15% (Supplemental tables ( Table 9) ). Dilution integrity was also evaluated at 50 and 100 fold level, however, unacceptable accuracies were usually obtained in some of the replicates leading to additional unacceptable precisions (data not shown). Nonetheless, there was not a single event during the analysis of 80 patient urine samples in which a 20 fold dilution was not sufficient to measure any of the derivatized metabolites existing outside their ULOQ.
Incurred sample reanalysis
Recent opinions suggest that despite the rigidity in validating bioanalytical methods; standards and QC samples may not entirely reflect the extent of the variation experienced in patient samples [65] .
Consequently, incurred sample reanalysis has been encouraged to be included within the validation studies [36, 65] . In some cases, significant differences in the concentrations of analytes were reported when study samples were reanalyzed despite the acceptance of the batch through the included QC samples [65] . Despite the absence of recommendations with the FDA, the EMA suggests that 10% of the samples should be reanalyzed if the studied samples are less than 1000.
The calculated concentrations should be within 20% of their mean in 67% of the repeats [36, 65] .
Accordingly, for a batch of 42 patient samples, aliquots from 4 selected patient urine samples were freshly thawed on 3 different days and analyzed in duplicates (6 replicates in total). For 2 patients, the concentrations of all quantified metabolites were below 17 % of their mean in at least 67% of the repeats (Table 3 ) meeting the specifications set by the EMA that is 20% in at least 67% [36, 65] . For 1 patient, 1 metabolite out of the 19 targets, 1-methylhistamine, showed unacceptable accuracies in 50% of the repeats specifically (%R = 71%, 121% and 125%). As for the last patient, percentage recoveries of alanine were possibly biased by the analyses obtained from day 3
(statistical outliers) ( Table 3 : Incurred sample reanalysis for 4 patient samples using the optimized analytical method
Analysis of patient samples
Figures 3A and 3B are representative extracted ion chromatograms obtained from urine sample analyzed from asthmatic and COPD patients, respectively. Histidine and glutamine, in most of the samples, were present at concentrations above their ULOQ and sample dilution was required for their quantification. Occasionally (less than 30% of the studied samples) alanine and taurine quantification needed sample dilution as well, and rare cases of out-of-the range high concentrations (less than 5% of the samples) were observed for tryptophan, valine, ethanolamine and threonine. One interesting finding is that creatinine concentration was not always indicative of other metabolite concentration despite having a constant output/day/subject [66] . For bromo and chloro-tyrosine, both of them were not detected within all patient samples. This agrees well with the literature in which specific sample pre-concentration and extraction steps were needed for their quantification [67, 68] .
Patient urine samples were analyzed by the developed methodology and data was analyzed using partial least square discriminant analysis (PLS-DA). Blinded asthma and COPD samples analyzed using SIMCA® software (Umetrics, Sweden) were adequately assigned with their correct diagnosis based on the concentration of metabolites included in the training set (data not shown).
The altered metabolites identified as the final biomarkers for differential diagnosis of asthma and COPD along with the involved biochemical pathways is outside the scope of this work, however, data generated from all metabolites previously identified from the 1 H-NMR will be compiled in a separate research article focusing on the clinical relevance.
Conclusion
An accurate, sensitive and validated method for the quantification of 19 urinary metabolites bearing amino and/or phenolic groups is successfully developed. The DIL approach is used so that conventional C18 column is applied with significant enhancement in ionization. Dansyl chloride was an excellent choice for derivatization as it allowed for the generation of an internal standard for each metabolite addressing matrix effects and any variations resulting from sample preparations. During method validation, key challenges were observed, particularly in the optimization the linear ranges for each metabolite in patient urine samples. Validation of selectivity was also halted by the presence of isotopic contribution from the light derivatized metabolites.
The statistical analysis using partial least square discriminant analysis (PLS-DA) from the dansylated metabolites will be combined with the results obtained from the remaining 50 target metabolites. The results from patient samples and the identified biomarkers for the differential diagnosis of asthma and COPD will be published in a separate research article where more emphasis on clinical aspect of the findings is discussed.
In summary, we have demonstrated the combination of DIL with LC-MS/MS analysis for targeted biomarker discovery. This technique can allow the development and validation of robust analytical methods needed for biomarkers quantification prior to FDA submission. By adopting this methodology, different submetabolome of carboxylic acids [58] , alcohols [69] and thiols [70] can be targeted and quantified. 
